- Home
- WSFS vs DNLI Comparison
WSFS vs DNLI Comparison
Compare WSFS & DNLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | WSFS | DNLI |
|---|---|---|
| Founded | 1980 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.8B | 3.0B |
| IPO Year | 1995 | 2017 |
Fundamental Metrics
Financial Performance| Metric | WSFS | DNLI |
|---|---|---|
| Price | $70.82 | $18.09 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 14 |
| Target Price | ★ $76.20 | $34.33 |
| AVG Volume (30 Days) | 315.7K | ★ 1.6M |
| Earning Date | 04-23-2026 | 05-06-2026 |
| Dividend Yield | ★ 1.12% | N/A |
| EPS Growth | ★ 15.42 | N/A |
| EPS | ★ 1.64 | N/A |
| Revenue | ★ $963,949,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.40 | $408.85 |
| P/E Ratio | $42.88 | ★ N/A |
| Revenue Growth | ★ 50.18 | N/A |
| 52 Week Low | $49.92 | $12.58 |
| 52 Week High | $73.22 | $23.77 |
Technical Indicators
Market Signals| Indicator | WSFS | DNLI |
|---|---|---|
| Relative Strength Index (RSI) | 53.48 | 38.54 |
| Support Level | $65.60 | $15.43 |
| Resistance Level | $71.30 | $19.17 |
| Average True Range (ATR) | 1.42 | 0.96 |
| MACD | -0.36 | -0.12 |
| Stochastic Oscillator | 42.60 | 12.85 |
Price Performance
Historical ComparisonAbout WSFS WSFS Financial Corporation
WSFS Financial Corp is a savings and loan holding company. The company operates in three segments: the WSFS Bank segment provides loans and leases, and other financial products to commercial and consumer customers; the Cash Connect segment provides ATM vault cash, smart safe, and other cash logistics services; and the Wealth and Trust segment provides a broad array of planning and advisory services, investment management, trust services, and credit and deposit products to individual, corporate, and institutional clients. The majority of revenue is generated from the WSFS Bank segment.
About DNLI Denali Therapeutics Inc.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegenerative diseases. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others. The Company has one operating segment with the goal to discover, develop, and commercializing therapeutics.